Research Study

A Phase 3, Randomized, Controlled, Double-Blind, Multinational Clinical Study of the Efficacy and Safety of Vosaroxin and Cytarabine Versus Placebo and Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (VALOR)
Principal Investigator 
Donna E. Hogge

Overview

Body Locations and Systems 
Leukemia
Disorders and Conditions 
Health Conditions 
Acute Myeloid Leukemia
ClinicalTrials.gov# 
NCT01191801
Status 
Closed to Recruitment
Study Start/End 
May 1, 2011 to May 1, 2016
Locations 
Vancouver General Hospital
Name/Title 
Mabel Ma, Research Assistant
Phone 
604-537-1433
Email Address 
mabel.ma@alumni.ubc.ca
Purpose of Study 

This study will compare the overall survival (OS) between treatment groups of patients treated with vosaroxin and cytarabine versus patients treated with placebo and cytarabine.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.